Zhejiang Wecome Pharmaceutical Company Limited (SHE:300878)
China flag China · Delayed Price · Currency is CNY
29.52
+0.92 (3.22%)
Nov 6, 2026, 11:05 AM CST

SHE:300878 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-126.57-227.34-147.43-8.9548.8196.5
Depreciation & Amortization
63.0362.7768.0746.6542.3826.99
Other Amortization
1.251.211.592.362.623.06
Loss (Gain) From Sale of Assets
0.990.990.470.010.63-0.07
Asset Writedown & Restructuring Costs
66.5366.5384.03-3.90.40.11
Loss (Gain) From Sale of Investments
11.3611.36-91.12-12.6-14.79-0.26
Provision & Write-off of Bad Debts
1.911.913.18-11.467.318.41
Other Operating Activities
-143.2333.6318.1811.96.082.21
Change in Accounts Receivable
165.64165.6472.9263.4238.67-151.67
Change in Inventory
57.4557.45-7.15-37.6-3.03-45.62
Change in Accounts Payable
-127.49-127.49-8.5424.558.7410.16
Operating Cash Flow
-8.6967.09-27.1758.29145.18-67.74
Operating Cash Flow Growth
----59.85%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-49.36-67.17-126.92-139.29-173.39-171.1
Sale of Property, Plant & Equipment
4.320.094.510.020.320.23
Cash Acquisitions
-----9.79-32.27
Divestitures
10.344.6337.32--13.69
Investment in Securities
-10-10241-240.57-5.16-2.91
Other Investing Activities
-0.01-106.76240.01-254.41-
Investing Cash Flow
-44.75-42.46188.299.31-442.43-192.35

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-65.3189.01377.04288.8150
Total Debt Issued
193.365.3189.01377.04288.8150
Short-Term Debt Repaid
-----0.5-
Long-Term Debt Repaid
--187.82-326.71-275-64.02-28.65
Lease Payments
---9.76-15-13.02-13.95
Total Debt Repaid
-231.82-187.82-326.71-275-64.52-28.65
Net Debt Issued (Repaid)
-38.52-122.52-137.69102.04224.2821.35
Repurchase of Common Stock
---50---
Common Dividends Paid
-7.79-28.42-44.4-7.02-45.74-80.99
Other Financing Activities
-0.11-0.11-22.550.25.68
Financing Cash Flow
-46.42-151.06-234.0997.57178.74-53.96

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Cash Flow
-99.86-126.42-72.97165.17-118.51-314.06

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-58.05-0.08-154.1-81-28.21-238.84
Free Cash Flow Growth
------
Free Cash Flow Margin
-23.01%-0.04%-43.88%-15.59%-5.30%-37.73%
Free Cash Flow Per Share
-0.40-0.00-1.08-0.54-0.20-1.66
Levered Free Cash Flow
-76.6213.93-84.38316-405.82-304.93
Unlevered Free Cash Flow
-76.2417.85-78.54321.9-402.44-303.58
Free Cash Flow After Leases
-58.05-0.08-163.85-96-41.24-252.79

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
17.997.7430.6734.2927.9869.23
Change in Working Capital
116.02116.0235.8534.2951.73-204.69